항비만 치료용 가역적 마오비 저해제
    72.
    发明公开
    항비만 치료용 가역적 마오비 저해제 有权
    抗肥胖治疗性可逆毛抑制剂

    公开(公告)号:KR1020170034071A

    公开(公告)日:2017-03-28

    申请号:KR1020150132281

    申请日:2015-09-18

    Abstract: 본발명은알파-아미노아미드유도체화합물및 이를포함하는항비만치료용약학조성물에관한것이다. 본발명의여러구현예에따르면상기알파-아미노아미드유도체는마오비와비공유결합을통해가역적으로마오비를억제할수 있으며, 종래의마오비저해제보다뛰어난안정성및 효능을가지므로마오비제어제로유용하게이용할수 있다. 또한선택적으로에너지소비를유도하는 POMC 신경세포에작용하여비만치료효과를나타낸다.

    Abstract translation: 本发明的α-涉及一种用于治疗肥胖的药物组合物,其中所述含氨基衍生物的化合物,和这一点。 根据本发明的各种实施例中,α-氨基 - 酰胺衍生物是可逆地并且可以抑制由于通过共价键毛非侘优异的稳定性和效力比常规毛比值抑制剂有用零毛比控制的毛比值, 可以使用。 也作用于POMC神经元选择性诱导能量消耗,以指示的肥胖的治疗效果。

    5-HT7 수용체에 작용하는 카바졸 유도체
    76.
    发明公开
    5-HT7 수용체에 작용하는 카바졸 유도체 有权
    在5-HT7受体上起作用的卡博唑衍生物

    公开(公告)号:KR1020150121897A

    公开(公告)日:2015-10-30

    申请号:KR1020140048074

    申请日:2014-04-22

    CPC classification number: C07D209/82 A61K31/33 A61K31/403 C07D209/80

    Abstract: 본발명은 5-HT수용체에작용하는카바졸유도체및 이의약제학적으로허용가능한염에관한것으로, 5-HT세로토닌수용체에대하여우수한결합친화력과우수한길항활성을가져 5-HT길항활성이요구되는우울증, 편두통, 불안, 통증, 염증성통증, 신경병성통증, 체온조절장애, 생체리듬조절장애, 수면장애및 평활근관련질환등의중추신경계질환의치료및 예방제로유용하게적용할수 있다.

    Abstract translation: 本发明涉及作用于5-HT_7受体的咔唑衍生物及其药学上可接受的盐,其中5-HT_7受体具有优异的结合亲和力和优异的拮抗活性,因此可用于应用于治疗和预防中枢的药剂 神经系统疾病如重症抑郁障碍,偏头痛,焦虑症,疼痛,炎症性疼痛,神经性疼痛,温度调节障碍,昼夜节律调节障碍,睡眠障碍和平滑肌相关疾病等,需要5-HT_7拮抗活性。

    신경보호제로서의 유레아 유도체
    78.
    发明公开
    신경보호제로서의 유레아 유도체 有权
    尿素类似物作为神经保护剂

    公开(公告)号:KR1020130115696A

    公开(公告)日:2013-10-22

    申请号:KR1020120038239

    申请日:2012-04-13

    Abstract: PURPOSE: A urea derivative is provided to selectively suppress the action of mPTP in the brain, thereby being used as a neuroprotective agent which improves the action of the mitochondria. CONSTITUTION: A urea derivative is denoted by chemical formula 1. A method for preparing the urea derivative comprises the steps of making a compound of chemical formula 2 react with isocyanate compounds or isothiocyanate compounds. The compound of chemical formula 2 is prepared by making a compound of chemical formula 3 react with benzyl halide compounds. A pharmaceutical composition for suppressing the action of mPTP contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for treating nervous diseases contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient.

    Abstract translation: 目的:提供尿素衍生物以选择性抑制脑中mPTP的作用,从而用作改善线粒体作用的神经保护剂。 构成:以化学式1表示脲衍生物。制备尿素衍生物的方法包括使化学式2的化合物与异氰酸酯化合物或异硫氰酸酯化合物反应的步骤。 通过使化学式3的化合物与苄基卤化合物反应来制备化学式2的化合物。 用于抑制mPTP作用的药物组合物含有尿素衍生物或其药学上可接受的盐作为活性成分。 用于治疗神经疾病的药物组合物含有尿素衍生物或其药学上可接受的盐作为活性成分。

    바이페닐 유도체, 이를 포함하는 약학 조성물 및 이의 제조방법
    79.
    发明公开
    바이페닐 유도체, 이를 포함하는 약학 조성물 및 이의 제조방법 无效
    联苯衍生物,包含其的药物组合物及其制备方法

    公开(公告)号:KR1020130058225A

    公开(公告)日:2013-06-04

    申请号:KR1020110124122

    申请日:2011-11-25

    Abstract: PURPOSE: A biphenyl derivative or a pharmaceutically acceptable salt thereof is provided to ensure excellent activity to 5-HT7 serotonin receptor and to be used as a preventive and therapeutic agent for depression, migraine, anxiety, pain especially inflammatory pain and neuropathy pain, bio rhythm, sleep, smooth muscle related diseases. CONSTITUTION: A biphenyl derivative is denoted by chemical formula 2. The biphenyl derivative has a structure of chemical formula 4 or 5. A pharmaceutical composition for preventing or treating diseases contains the biphenyl derivative or a pharmaceutically acceptable salt thereof. A method for preparing the biphenyl derivative of chemical formula 2 comprises: a step of performing Suzuki coupling of aryl boronic acid of chemical formula 6 and bromobenzene aldehyde of chemical formula 7 to prepare a biphenyl aldehyde intermediate of chemical formula 8; and a step of performing reductive amination of the biphenyl aldehyde intermediate with arylpiperazine of chemical formula 9.

    Abstract translation: 目的:提供联苯衍生物或其药学上可接受的盐,以确保对5-HT7血清素受体的优异活性,并用作抑郁症,偏头痛,焦虑症,疼痛,特别是炎性疼痛和神经病疼痛,生物节律的预防和治疗剂 ,睡眠,平滑肌相关疾病。 构成:联苯衍生物由化学式2表示。联苯衍生物具有化学式4或5的结构。用于预防或治疗疾病的药物组合物含有联苯衍生物或其药学上可接受的盐。 制备化学式2的联苯衍生物的方法包括:进行化学式6的芳基硼酸和化学式7的溴苯醛的Suzuki偶联以制备化学式8的联苯醛中间体的步骤; 以及用化学式9的芳基哌嗪进行联苯醛中间体的还原胺化的步骤。

    T-형 칼슘 채널 길항제로서의 5-(치환된알킬아미노메틸)아이속사졸계 화합물
    80.
    发明公开
    T-형 칼슘 채널 길항제로서의 5-(치환된알킬아미노메틸)아이속사졸계 화합물 有权
    5-(取代的烷基氨基甲酰基)异噻唑衍生物作为T型钙通道拮抗剂

    公开(公告)号:KR1020120096842A

    公开(公告)日:2012-08-31

    申请号:KR1020110016203

    申请日:2011-02-23

    CPC classification number: C07D413/12

    Abstract: PURPOSE: A 5-(substituted alkylaminomethyl)isoxazole based compound as T-type calcium channel blocker is provided to have excellent activity as an antagonist of T- type calcium ion channel. CONSTITUTION: A 5-(substituted alkylaminomethyl)isoxazole based compound as T-type calcium channel blocker is represented by chemical formula 1. The encephalopathy therapy and for prevention agent selected from epilepsy, depression, Parkinson's disease, dementia, sleep disorder, an agent for cancer treatment and prevention, an agent for heart disease treatment and prevention selected from hypertensive, cardiac arrhythmia, angina, myocardial infarction, congestive heart failure, pharmaceutical composition for alleviating pain selected from neuropathic pain and chronic and acute pain includes a compound represented by chemical formula 1.

    Abstract translation: 目的:提供作为T型钙通道阻滞剂的5-(取代的烷基氨基甲基)异恶唑基化合物作为T-型钙离子通道的拮抗剂具有优异的活性。 构成:以化学式1表示作为T型钙通道阻断剂的5-(取代烷基氨基甲基)异恶唑类化合物。脑病治疗和预防药物选自癫痫,抑郁症,帕金森病,痴呆,睡眠障碍, 癌症治疗和预防,选自高血压,心律失常,心绞痛,心肌梗塞,充血性心力衰竭,减轻选自神经性疼痛和慢性和急性疼痛的疼痛的药物组合物的心脏病治疗和预防剂,包括由化学式 1。

Patent Agency Ranking